此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Comparison of Growth Factor Releases and Degradation Rates of Membranes Obtained From A-PRF+, L-PRF, and Alb-PRF (PRF)

2026年8月20日 更新者:Hülya Anak、Izmir Katip Celebi University
Platelet-rich fibrin (PRF) is widely used in regenerative dentistry because of its autologous growth factor release and fibrin scaffold properties. Different PRF preparations may exhibit different biological characteristics that influence their clinical performance. This study aims to compare Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) regarding cumulative growth factor release and fibrin degradation. Blood samples obtained from healthy volunteers will be processed to prepare all three PRF types. Growth factor release and fibrin degradation will be analyzed under standardized laboratory conditions.

研究概览

详细说明

Platelet-rich fibrin products have become increasingly popular in regenerative medicine because they provide a fibrin scaffold capable of releasing multiple growth factors over time. However, differences in centrifugation protocols and preparation techniques may significantly affect their biological properties.

Albumin-PRF is a recently introduced modification that combines heat-denatured plasma proteins with injectable PRF to increase scaffold stability and prolong growth factor release.

This study will compare Alb-PRF, A-PRF+, and L-PRF prepared from the same healthy volunteers. Cumulative release of VEGF, PDGF-BB, and TGF-β1 will be evaluated on Days 1, 3, 5, and 7 using ELISA. Resistance to enzymatic degradation will be assessed by measuring delta D-dimer concentrations following trypsin-EDTA exposure. The results are expected to improve understanding of the biological performance of different PRF formulations.

研究类型

介入性

注册 (实际的)

10

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • İzmir
      • Izmir、İzmir、土耳其(türkiye)、35620
        • Izmir Katip Celebi University Faculty of Dentistry

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人

接受健康志愿者

是的

描述

Inclusion Criteria:

  • Healthy volunteers aged 18 to 40 years
  • Male or female
  • Able and willing to provide written informed consent
  • Non-smokers
  • No history of systemic disease
  • No regular medication use
  • No use of antibiotics, corticosteroids, or non-steroidal anti-inflammatory drugs within the previous 6 months

Exclusion Criteria:

  • Age younger than 18 years or older than 40 years
  • Smoking
  • Pregnancy or breastfeeding
  • History of any systemic disease
  • Regular medication use
  • Use of antibiotics, corticosteroids, or non-steroidal anti-inflammatory drugs within the previous 6 months
  • Refusal or inability to provide written informed consent

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:非随机化
  • 介入模型:交叉作业
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Albumin-Platelet Rich Fibrin (Alb-PRF)
Blood samples obtained from healthy volunteers were processed using the Albumin-Platelet Rich Fibrin (Alb-PRF) protocol. Growth factor release and resistance to enzymatic degradation were evaluated under standardized laboratory conditions.
Autologous Albumin-Platelet Rich Fibrin prepared from peripheral venous blood using the Alb-PRF protocol for evaluation of growth factor release and enzymatic degradation.
实验性的:Leukocyte-Platelet Rich Fibrin (L-PRF)
Blood samples obtained from healthy volunteers were processed using the Leukocyte-Platelet Rich Fibrin (L-PRF) protocol. Growth factor release (VEGF, PDGF-BB, and TGF-β1) and resistance to enzymatic degradation were evaluated under standardized laboratory conditions and compared with Albumin-PRF (Alb-PRF) and Advanced Platelet-Rich Fibrin+ (A-PRF+).
Autologous Leukocyte-Platelet Rich Fibrin prepared from peripheral venous blood using the L-PRF protocol for evaluation of growth factor release and enzymatic degradation.
实验性的:Advanced - Platelet Rich Fibrin+ (A-PRF+)
Blood samples obtained from healthy volunteers were processed using the Advanced Platelet-Rich Fibrin+ (A-PRF+) protocol. Growth factor release (VEGF, PDGF-BB, and TGF-β1) and resistance to enzymatic degradation were evaluated under standardized laboratory conditions and compared with Albumin-PRF (Alb-PRF) and Leukocyte-Platelet Rich Fibrin (L-PRF) .
Autologous Advanced Platelet-Rich Fibrin+ prepared from peripheral venous blood using the A-PRF+ protocol for evaluation of growth factor release and enzymatic degradation.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
VEGF concentration released from PRF membranes
大体时间:Day 1, Day 3, Day 5, and Day 7
Quantitative assessment of VEGF released from Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) using enzyme-linked immunosorbent assay (ELISA).
Day 1, Day 3, Day 5, and Day 7
PDGF concentration released from PRF membranes
大体时间:Day 1, Day 3, Day 5, and Day 7
Quantitative assessment of PDGF released from Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) using enzyme-linked immunosorbent assay (ELISA).
Day 1, Day 3, Day 5, and Day 7
TGF-B concentration released from PRF membranes
大体时间:Day 1, Day 3, Day 5, and Day 7
Quantitative assessment of TGF-B released from Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) using enzyme-linked immunosorbent assay (ELISA).
Day 1, Day 3, Day 5, and Day 7
Resistance to enzymatic degradation
大体时间:60 minutes and 120 minutes
Assessment of fibrin degradation by measuring D-dimer levels after enzymatic digestion of PRF preparations.
60 minutes and 120 minutes

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年1月1日

初级完成 (实际的)

2026年3月1日

研究完成 (实际的)

2026年5月1日

研究注册日期

首次提交

2026年7月29日

首先提交符合 QC 标准的

2026年8月20日

首次发布 (实际的)

2026年8月21日

研究记录更新

最后更新发布 (实际的)

2026年8月21日

上次提交的符合 QC 标准的更新

2026年8月20日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

其他研究编号

  • 2025-TDU-DİŞF-0014

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅